Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Abstract Background Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicity. The newer anti-tuberculosis drugs, bedaquiline...

Descrizione completa

Dettagli Bibliografici

Autori principali:	S. B. Patil, M. Tamirat, K. Khazhidinov, E. Ardizzoni, M. Atger, A. Austin, E. Baudin, M. Bekhit, S. Bektasov, E. Berikova, M. Bonnet, R. Caboclo, M. Chaudhry, V. Chavan, S. Cloez, J. Coit, S. Coutisson, Z. Dakenova, B. C. De Jong, C. Delifer, S. Demaisons, J. M. Do, D. Dos Santos Tozzi, V. Ducher, G. Ferlazzo, M. Gouillou, U. Khan, M. Kunda, N. Lachenal, A. N. LaHood, L. Lecca, M. Mazmanian, H. McIlleron, M. Moreau, M. Moschioni, P. Nahid, E. Osso, L. Oyewusi, S. Panda, A. Pâquet, P. Thuong Huu, L. Pichon, M. L. Rich, P. Rupasinghe, N. Salahuddin, E. Sanchez Garavito, K. J. Seung, G. E. Velásquez, M. Vallet, F. Varaine, F. J. Yuya-Septoh, C. D. Mitnick, L. Guglielmetti
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2023-11-01
Serie:	Trials
Soggetti:	Fluroquinolone-resistant Pre-XDR TB Multidrug-resistant Rifampicin-resistant MDR-TB RR-TB
Accesso online:	https://doi.org/10.1186/s13063-023-07701-6
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!